Navigation Links
New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
Date:5/19/2008

San Diego, CA May 18, 2008 New study results indicated that treatment with AMITIZA (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bowel Syndrome with Constipation (IBS-C). These results were presented at Digestive Disease Week (DDW) 2008, the largest annual international meeting of digestive disease specialists.

IBS-C is a multi-symptom disorder and is one of the most common conditions seen by gastroenterologists, said William D. Chey, M.D., primary investigator of the study, University of Michigan Health System. These data are important because they show that in studies, AMITIZA has demonstrated the ability to improve the overall symptoms reported by patients with IBS-C.

AMITIZA 8 mcg was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2008 for the treatment of IBS-C in women 18 years of age and older, and has been approved since 2006 at a 24 mcg dose for the treatment of Chronic Idiopathic Constipation in adults. These data were among others presented at DDW 2008 that evaluated the effect of AMITIZA for IBS-C.

AMITIZA is the first ClC-2 channel activator and the only widely available FDA-approved agent for the treatment of IBS-C in adult women in the United States. AMITIZA could provide overall symptom relief for the millions of appropriate patients in the U.S. who suffer from this condition, said Ryuji Ueno, M.D., Ph.D., Ph.D., founder, chairman and chief executive officer, Sucampo Pharmaceuticals (NASDAQ: SCMP). We are pleased with the body of data on AMITIZA presented at DDW this year. Additional data presented at this meeting may help physicians better understand how to treat their patients with IBS-C.

AMITIZA makes it possible for appropriate patients to receive a widely available FDA-approved treatment for their IBS-C, said Charles Baum, M.D., gastroenterologist and executive medical director, Gastroenterology and Internal Medicine, Takeda Pharmaceuticals North America, Inc.

Approximately 58 million Americans have Irritable Bowel Syndrome (IBS), and IBS-C accounts for approximately one-third of these cases. IBS-C is a chronic disorder characterized by abdominal discomfort or pain and changes in bowel habits including symptoms of constipation.


'/>"/>

Contact: Valerie Rinaldi
valerie.rinaldi@ketchum.com
646-935-4178
Ketchum
Source:Eurekalert

Related medicine news :

1. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
2. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
3. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
4. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
5. Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting
6. Wal-Mart Launches Phase Three of $4 Prescription Program
7. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
8. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
9. Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
10. QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension
11. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 05, 2016 , ... Love is in the air at King Kullen! The ... and packaging. This staple for Valentine’s Day is a must-have, and can be picked ... Day, not only are long-stem roses available, but also other flower bouquets, elegantly wrapped ...
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... George H. Van Allen have signed a joint enrollment and degree completion agreement. ... pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... FOSTER CITY, Calif. , Feb. 4, 2016 ... (the "Company") today announced it has entered into ... and Exchange Commission (SEC) fully resolving the SEC,s ... Practices Act (FCPA).  Under the terms of the ... total of $12.8 million, including disgorgement, pre-judgment interest ...
(Date:2/4/2016)... Feb. 4, 2016 Frontier Pharma: Chronic ... First-in-Class Innovation Chronic Obstructive Pulmonary ... chronic inflammation of the airways and lungs. Persistent ... make the disease one of the leading causes ... in the world. COPD is linked to cumulative ...
(Date:2/4/2016)... 2016  AMRI (NASDAQ:  AMRI) today announced that Anthony ... President of Pfizer Global Supply, has been elected to the ... In addition, the Company announced that Mr. Gabe Leung ... 2010, has retired from the AMRI Board of Directors in ... business ventures.  William S. Marth , President ...
Breaking Medicine Technology: